McKenna's Drug Handbook for Nursing & Midwifery, 7e

98 Diagnostic preparations

exametazime gadobenate dimeglumine gadobutrol gadodiamide

Adults: 350–500 MBq IV. Dynamic imaging may be performed between 0 and 10 minutes following injection. Static imaging may be performed from 15 minutes up to 6 hours after injection. Action Diagnostic radiopharmaceutical preparation that assists detection of altered perfusion in areas of the cerebrum. Route Onset Peak Duration IV Immediate Unknown 6 hrs Adverse reactions CV: transient blood pressure elevation, vascular spasm. Skin: rash, urticaria. Other: facial or generalised oedema, fever, mild hypersensitivity. Interactions None reported. Contraindications Contraindicated in individuals with known hypersensitivity to the preparation. care considerations • Alert: Radioactive drug—drug must be handled with care and appropriate safety measures should be used to minimise radiation exposure to the individual and to staff. • Reconstituted agent must be used within 30 minutes. • Monitor blood pressure following procedure. • Due to potential for bladder radiation, encourage person to follow adequate hydration and to void straight after the procedure, then regularly thereafter. • Women who are breastfeeding should discontinue breastfeeding for at least

gadopentetate gadoteric acid gadoteridol gadoxetic acid iodixanol iohexol iomeprol

iopamidol iopromide ioversol meglumine iothalamate meglumine iotroxate metyrapone tetrofosmin thyrotrophin alfa Combination products

G astrografin ,M d -76,M d - gastroview :sodium diatrizoate 10% and meglumine diatrizoate 66%. U rografin 30%: sodium amidotrizoate 40 mg/mL and meglumine amidotrizoate 260 mg/mL. U rografin 76%: sodium amidotrizoate 100 mg/mL and meglumine amidotrizoate 660 mg/mL. exametazime Ceretec Pregnancy risk category C Use in sport: Permitted Available form Solution for injection: 0.5 mg/0.5 mL Indications & dosages ➤ Scintigraphic identification of seizure foci in individualswithtemporal lobeepilepsy—